Related Experiment Video
Updated: Jun 4, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents
Chengliang Sun1,2,3, Yao Cheng1,4, Jingwen Dong5
1State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Abstract:
Inhibiting the activity of immune checkpoint proteins to reignite the antitumor activity of immune cells has emerged as a pivotal strategy. PD-L1 and VISTA, as critical proteins governing immune regulation, are concurrently upregulated under conditions such as hypoxia. Through a rational drug design process, P17, a dual-target inhibitor for PD-L1 and VISTA is identified. This inhibitor blocks the signaling pathways of both PD-L1 and VISTA at the protein and cellular levels, thereby reactivating the antitumor function of T cells. P17 displays encouraging attributes in terms of druggability and safety assessments. Notably, P17 demonstrates superior antitumor efficacy compared to single-target inhibitors at equivalent doses in in vivo experiments. More crucially, P17 significantly enhances the infiltration of immune cells. This study not only validates the effectiveness of a dual-target inhibitor strategy against PD-L1 and VISTA, but also identifies P17 as a promising candidate molecule with significant therapeutic potential.
Insights
A novel dual-target inhibitor, P17, effectively blocks PD-L1 and VISTA immune checkpoints to restore T cell antitumor activity. This promising drug candidate demonstrates superior efficacy and enhances immune cell infiltration in preclinical models.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Immune checkpoint inhibitors (ICIs) are crucial for cancer immunotherapy.
- PD-L1 and VISTA are key immune regulatory proteins often upregulated in tumors.
- Targeting these checkpoints can restore anti-tumor immune responses.
Purpose of the Study:
- To identify and characterize a novel dual-target inhibitor for PD-L1 and VISTA.
- To evaluate the efficacy and safety of the identified inhibitor, P17.
- To assess the potential of dual-targeting PD-L1 and VISTA in cancer therapy.
Main Methods:
- Rational drug design was employed to identify P17.
- In vitro assays assessed P17's inhibitory effects on PD-L1 and VISTA signaling.
- In vivo experiments evaluated P17's anti-tumor efficacy and immune cell infiltration.
Main Results:
- P17 was identified as a dual inhibitor of PD-L1 and VISTA.
- P17 effectively blocked PD-L1 and VISTA at protein and cellular levels, reactivating T cells.
- P17 demonstrated superior anti-tumor efficacy and enhanced immune cell infiltration compared to single-target inhibitors in vivo.
- P17 exhibited favorable druggability and safety profiles.
Conclusions:
- Dual-targeting of PD-L1 and VISTA is a viable therapeutic strategy.
- P17 is a promising drug candidate with significant therapeutic potential for cancer treatment.
- P17 warrants further investigation for its clinical application in immunotherapy.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...